Insight Molecular Diagnostics (0KCC) Financial Statements
Insight Molecular Diagnostics Financial Overview
Insight Molecular Diagnostics's market cap is currently $96.86M. The company's EPS TTM is $-1.52; its P/E ratio is -1.95; and it has a dividend yield of 1.14%. Insight Molecular Diagnostics is estimated to report earnings on November 5, 2026, and the estimated EPS forecast is $-0.24. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Mar 24 | Mar 23 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 4.05M | $ 1.88M | $ 1.50M | $ 958.00K | $ 2.20M |
| Gross Profit | $ 190.00K | $ 740.00K | $ 413.00K | $ -18.00K | $ 1.42M |
| Operating Income | $ -30.58M | $ -61.04M | $ -25.14M | $ -18.00M | $ -53.73M |
| EBITDA | $ -47.92M | $ -59.02M | $ -23.12M | $ -13.31M | $ -48.46M |
| Net Income | $ -50.22M | $ -60.66M | $ -27.78M | $ -72.90M | $ -64.10M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 11.58M | $ 8.64M | $ 9.43M | $ 20.43M | $ 33.85M |
| Total Assets | $ 25.76M | $ 35.08M | $ 74.89M | $ 100.09M | $ 159.56M |
| Total Debt | $ 3.50M | $ 3.66M | $ 2.87M | $ 3.54M | $ 5.68M |
| Net Debt | $ -8.09M | $ -4.97M | $ -6.56M | $ -16.45M | $ -27.27M |
| Total Liabilities | $ 57.22M | $ 47.35M | $ 54.42M | $ 60.50M | $ 94.35M |
| Stockholders' Equity | $ -31.46M | $ -12.27M | $ 20.47M | $ 39.59M | $ 65.22M |
| Cash Flow | |||||
| Free Cash Flow | $ -25.37M | $ -21.23M | $ -23.61M | $ -49.91M | $ -38.19M |
| Operating Cash Flow | $ -22.18M | $ -20.71M | $ -23.32M | $ -45.57M | $ -35.94M |
| Investing Cash Flow | $ -3.19M | $ -512.00K | $ -932.00K | $ -4.34M | $ -13.96M |
| Financing Cash Flow | $ 28.07M | $ 20.43M | $ 12.19M | $ 35.81M | $ 78.36M |
Currency in USD